CSBR — Champions Oncology, Inc.

Champions Oncology (CSBR) Q3 Fiscal 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $16.6 million, a decrease of approximately 3% from $17 million in Q3 FY2025.
• Core Study Revenue: Record high of $16.6 million, up 32% year-over-year from $12.6 million.
• Data Revenue: No revenue recognized this quarter compared to $4.5 million in the prior year, contributing to the overall decline.
• Adjusted EBITDA: Positive adjusted EBITDA of $575,000 for the third consecutive quarter.
• GAAP Loss from Operations: Approximately $275,000.
• Gross Margin: 47%, down from 61% year-over-year, impacted by outsourced laboratory costs.
• Operating Expenses: Increased to $7.2 million from $5.3 million, reflecting strategic investments.
• Cash Position: Ended the quarter with $7.1 million in cash and no debt.

2. Strategic Updates and Business Highlights:

• Continued strong operational performance with record services revenue and positive adjusted EBITDA.
• Notable growth in core services, attributed to strong execution and conversion of previously booked work.
• Early momentum in the data business with new deals closed and expectations for revenue recognition in Q4.
• Corellia, the target discovery subsidiary, is generating positive feedback and is included in fiscal 2027 budgeting.
• The company is focused on maintaining a balance between growth investments and profitability.

3. Forward Guidance and Outlook:

• Champions Oncology remains on track for full-year revenue growth and positive adjusted EBITDA.
• Anticipates normalization of revenue as studies progress, but underlying demand for services is healthy.
• Investments in data and drug discovery are expected to yield results starting in fiscal 2027, with acceleration anticipated in fiscal 2028.
• The company is committed to disciplined capital allocation while pursuing growth opportunities.

4. Bad News, Challenges, or Points of Concern:

• Year-over-year revenue decline primarily due to the absence of data revenue, which is expected to be volatile in the near term.
• Gross margin pressures due to increased costs from outsourced laboratory work, although there are plans to bring this work in-house to improve margins.
• Operating expenses have risen significantly, which may impact short-term profitability.
• The timing of external funding for Corellia remains uncertain, which could affect financial flexibility.

5. Notable Q&A Insights:

• There were no questions from analysts during the call, indicating either satisfaction with the information provided or a lack of immediate concerns from stakeholders.

Overall, Champions Oncology reported a solid quarter with strong core services performance but faced challenges in data revenue recognition and margin pressures. The company is optimistic about future growth driven by strategic investments and operational improvements.